SEC Comment Letter for IGC Pharma, Inc. (IGC) (CIK 0001326205) (IGC) — Nov 7, 2011
IGC Pharma, Inc. (IGC) (CIK 0001326205)
Date: Nov. 7, 2011 · CIK: 0001326205 · Accession: 0000000000-11-064738
AI Filing Summary & Sentiment
Reasoning
Letter
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 DIVISION OF CORPORATION FINANCE November 7, 2011 Via Facsimile Mr. John B. Selvaraj Principal Accounting Officer India Globalization Capital, Inc. 4336 Montgomery Ave. Bethesda, Maryland 20814 RE: India Globalization Capital, Inc. Form 10-K for the Year Ended March 31, 2011 Filed July 14, 2011 Definitive Proxy Statement on Schedule 14A Filed August 1, 2011 File No. 1-32830
Dear Mr. Selvaraj:
We have completed our review of your filings . We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commissi on from taking any action with respect to the company or the filing and the company may not assert st aff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are resp onsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filin g includes the information the Securities Exchange Act of 1934 and all applicab le rules require.
S i n c e r e l y , / s / R u f u s D e c k e r R u f u s D e c k e r Accounting Branch Chief
Show Raw Text
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
DIVISION OF
CORPORATION FINANCE
November 7, 2011
Via Facsimile
Mr. John B. Selvaraj Principal Accounting Officer India Globalization Capital, Inc. 4336 Montgomery Ave. Bethesda, Maryland 20814
RE: India Globalization Capital, Inc.
Form 10-K for the Year Ended March 31, 2011 Filed July 14, 2011 Definitive Proxy Statement on Schedule 14A Filed August 1, 2011 File No. 1-32830
Dear Mr. Selvaraj:
We have completed our review of your filings . We remind you that our comments or changes
to disclosure in response to our comments do not foreclose the Commissi on from taking any action
with respect to the company or the filing and the company may not assert st aff comments as a defense
in any proceeding initiated by the Commission or any person under the federal securities laws of the
United States. We urge all persons who are resp onsible for the accuracy and adequacy of the
disclosure in the filing to be certain that the filin g includes the information the Securities Exchange Act
of 1934 and all applicab le rules require.
S i n c e r e l y ,
/ s / R u f u s D e c k e r R u f u s D e c k e r
Accounting Branch Chief